Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change

[1]  H. Harapan,et al.  Remdesivir and its antiviral activity against COVID-19: A systematic review , 2020, Clinical Epidemiology and Global Health.

[2]  A. Musa,et al.  Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature , 2020, The western journal of emergency medicine.

[3]  F. Selina,et al.  Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences. , 2020, Mymensingh Medical Journal.

[4]  R. Montironi,et al.  Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients , 2020, Clinical Drug Investigation.

[5]  M. Sydes,et al.  Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement , 2020, British Journal of Cancer.

[6]  M. Mansourian,et al.  Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis. , 2020, American journal of therapeutics.

[7]  R. Autorino,et al.  New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis. , 2020, The Journal of urology.

[8]  N. Lawrentschuk,et al.  Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. , 2020, European urology.

[9]  S. Qu,et al.  Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis , 2019, Cost effectiveness and resource allocation : C/E.

[10]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[11]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[12]  Tetsuro Ito,et al.  Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis , 2019, European urology. Supplement.

[13]  S. Halabi,et al.  Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. , 2019, European urology focus.

[14]  H. Zeng,et al.  What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. , 2018, Urologic oncology.

[15]  Tetsuro Ito,et al.  Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. , 2018, European journal of cancer.

[16]  A. Mandal,et al.  STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs , 2018, Indian journal of urology : IJU : journal of the Urological Society of India.

[17]  P. Aguiar,et al.  Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis , 2018, Prostate Cancer and Prostatic Diseases.

[18]  S. Qu,et al.  Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (mHSPC): An updated network meta-analysis and cost minimization analysis in China. , 2018 .

[19]  A. Giglio,et al.  Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer. , 2018 .

[20]  K. Shohdy,et al.  Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy , 2018, Current medical research and opinion.

[21]  M. Kohli,et al.  Abiraterone acetate (AA) or docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs). , 2018 .

[22]  B. Firwana,et al.  Treatments for metastatic hormone-sensitive prostate cancer: A systematic review. , 2018 .

[23]  C. Catton,et al.  Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity. , 2018 .

[24]  H. Zeng,et al.  Is it the time to shift paradigms in castration naïve prostate cancer (CNPC): A meta-analysis of upfront docetaxel and abiraterone in men with CNPC. , 2018 .

[25]  M. Parmar,et al.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  I. White,et al.  What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  S. Boorjian,et al.  Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. , 2017, European urology.

[28]  F. Boccardo,et al.  Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! , 2018, European urology.

[29]  E. Antonarakis,et al.  The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation , 2017, Prostate Cancer and Prostatic Diseases.

[30]  J. Ioannidis,et al.  Overlapping network meta-analyses on the same topic: survey of published studies. , 2017, International journal of epidemiology.

[31]  E. El Rassy,et al.  The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel? , 2017, Future oncology.

[32]  M. Parmar,et al.  Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis , 2017, European journal of cancer.

[33]  M. Sydes,et al.  LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476) , 2017 .

[34]  B. Yalcin,et al.  Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer. , 2017, Future oncology.

[35]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[36]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[37]  M. Parmar,et al.  Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Carpenter,et al.  Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? , 2017, British Medical Journal.

[39]  A. de Laat,et al.  Network meta-analysis. , 2017, Journal of oral rehabilitation.

[40]  R. DiPaola,et al.  Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial , 2016 .

[41]  S. Culine,et al.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.

[42]  G. Guyatt,et al.  Living cumulative network meta-analysis to reduce waste in research: A paradigmatic shift for systematic reviews? , 2016, BMC Medicine.

[43]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[44]  M. Parmar,et al.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.

[45]  P. Kantoff,et al.  The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). , 2015, Journal of the National Cancer Institute.

[46]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[47]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[48]  Tari Turner,et al.  Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap , 2014, PLoS medicine.

[49]  D. Moher.  The problem of duplicate systematic reviews , 2013, BMJ.

[50]  Tina Hernandez-Boussard,et al.  Overlapping meta-analyses on the same topic: survey of published studies , 2013, BMJ.

[51]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[52]  M. Parmar,et al.  Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial , 2012, Trials.

[53]  Georgia Salanti,et al.  Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool , 2012, Research synthesis methods.

[54]  Nicky J Welton,et al.  How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[55]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[57]  T. Fujioka,et al.  A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer , 2006, International Journal of Clinical Oncology.

[58]  K. Itoh,et al.  Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone‐releasing hormone agonist versus flutamide plus luteinizing hormone‐releasing hormone agonist , 2004, International journal of urology : official journal of the Japanese Urological Association.

[59]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[60]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.